Plain-English translation of NCT07136714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Major Depressive Disorder research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This 26-week study is testing whether semaglutide (a once-weekly injection medication) can improve depressive symptoms in people who have depression and are overweight or living with obesity. Half of the participants will receive the medication, and half will receive a placebo (a saline injection with no active drug). Researchers will measure changes in mood and depression symptoms throughout the trial.
Depression and weight gain often occur together, and current depression treatments don't always work well for everyone. This study explores whether this medication—which is already known to help with weight loss—might also help improve mood and depressive symptoms.
You likely qualify if…
You likely don't qualify if…
You will come in for visits at weeks 0, 4, 8, 12, 16, 20, 24, and 26. At each visit, you'll receive either the medication or a placebo as a once-weekly injection under the skin. The medication dose will gradually increase over the first 16 weeks. Throughout the study, you'll complete mood and depression questionnaires, have your blood pressure and weight checked, and answer questions about your physical activity, sleep, stress, and quality of life.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Denmark